Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug-Reference-Cited by-同舟云学术

Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug

Published:1992-01 Issue:3 Volume:56 Page:323-339
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Tew Kenneth D.,Glusker Jenny P.,Hartley-Asp Beryl,Hudes Gary,Speicher Lisa A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference74 articles.

1. Preliminary results of Phase II trial of estramustine and vinblastine for patients with progressive hormone refractory prostate carcinoma;Amato,1991

2. Estramustine phosphate therapy in carcinoma of the prostate;Anderson,1977

3. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites;Bai;J. biol. Chem.,1990

4. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10;Bai;Biochem. Pharmac.,1990

5. Estramustine phosphate compared with diethylstilbestrol;Benson;Am. J. clin. Oncol.,1986

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LYSOPHOSPHATIDIC ACID MODIFIES THE RESPONSE OF PC3 PROSTATE CANCER CELLS TO CHEMOTHERAPEUTICS;WORLD CANCER RES J;2020

2. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer;Medicine;2016-09

3. Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies;Biomedicine & Pharmacotherapy;2012-09

4. Alkylating Agents;Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures;2010-11-03

5. Docetaxel;Drug Management of Prostate Cancer;2010